Illumina, Inc. vs Nokia Corp — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while Nokia Corp trades at $10.36 (market cap $56.99B). The key difference: Nokia Corp is the larger of the two by market cap, and Nokia Corp pays a 1.61% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Nokia Corp for 66 Days on average.
| ILMN | NOK | |
|---|---|---|
Market Cap | $39.95B | $56.99B |
Volume | 3,169,503 | 69,968,204 |
Sector | Health | Technology |
52-Week High | $293.69 | $16.83 |
52-Week Low | $91.00 | $5.25 |
Typical Hold Time | 83 Days | 66 Days |
Enterprise Value | $41.31B | $55.01B |
Dividend Yield | — | 1.61% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 1.25% on the day but remains near its 52-week high of $278.99, reflecting strong momentum with a 94.9% YTD gain. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Fundamentals show a significant turnaround, with net income reaching $850 million in 2025 after prior losses, supported by robust gross margins of 66.38%. Technical indicators are bullish overall, with key support at $257 and resistance at $268.
The outlook for ILMN is positive, driven by earnings momentum, inclusion in the S&P 500, and strategic AI initiatives in genomics. However, risks include high valuation multiples, such as a P/E of 49.36, and potential margin pressure from cost volatility. Analyst consensus is bullish with a 54% buy rating, though the consensus price target of $241 suggests limited near-term upside from current levels.
Nokia (NOK) trades at $10.14, down 4.52% over 24 hours, with a bearish technical signal. The stock shows mixed earnings, beating estimates in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue has stabilized around $20B annually, with a net income margin of 3.47% in 2025. Analyst consensus is bullish, with a $17.50 price target, supported by recent partnerships in AI and satellite communications.
The outlook is cautiously optimistic, driven by AI infrastructure demand and strategic alliances, but risks include competitive pressures and volatile cash flows. Upside potential exists if execution on growth initiatives improves profitability, while downside risks stem from macroeconomic headwinds and execution missteps.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →